There are 3161 resources available
861P - Neo-TIME trial: Neoadjuvant tislelizumab combined with albumin-paclitaxel, cisplatin, and fluorouracil(APF) in patients with locally advanced oral squamous cell carcinoma (LA-OSCC)
Presenter: Wenquan Zhao
Session: Poster session 02
862P - Neoadjuvant chemo-immunotherapy using carboplatin, nab-paclitaxel, oral metronomic therapy and low dose nivolumab for “borderline resectable” oral cavity carcinoma: A prospective phase II single-arm trial (NeoLOCUS)
Presenter: Praveen Kumar Marimuthu
Session: Poster session 02
863P - Safety and efficacy of four courses of pembrolizumab combined with carboplatin and albumin-binding paclitaxel versus two courses of neoadjuvant therapy in patients with resectable head and neck squamous cell carcinoma: An optimal efficacy study (prospective, two-arm, phase II)
Presenter: Jinsong Li
Session: Poster session 02
Resources:
Abstract
866P - Neoadjuvant and adjuvant AK104 in patients with recurrent, resectable squamous cell carcinoma of the head and neck: A phase II study
Presenter: Lei Liu
Session: Poster session 02
868P - Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Presenter: Winston Wong
Session: Poster session 02
869P - Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab (D) combined with weekly paclitaxel carboplatin in 1st-line in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible to cisplatin
Presenter: Jérome Fayette
Session: Poster session 02